医学综述
醫學綜述
의학종술
MEDICAL RECAPITULATE
2015年
3期
531-533
,共3页
李晖云%于磊%曹赛霞%杨书彦%刘国平%龚莉
李暉雲%于磊%曹賽霞%楊書彥%劉國平%龔莉
리휘운%우뢰%조새하%양서언%류국평%공리
系统性红斑狼疮%狼疮性肾炎%尿脂质运载蛋白2%诊断意义
繫統性紅斑狼瘡%狼瘡性腎炎%尿脂質運載蛋白2%診斷意義
계통성홍반랑창%랑창성신염%뇨지질운재단백2%진단의의
Systemic lupus erythematosus%Lupus nephritis%Urinary lipid carrier protein-2%Diagnostic significance
目的:探讨尿脂质运载蛋白2(uLn-2)在狼疮性肾炎(LN)患者早期诊断中的临床意义。方法选取2010年3月至2013年9月内蒙古自治区人民医院肾内科收治的107例LN患者为研究对象,根据尿液中微量白蛋白(mAlb)水平分为Ⅰ组(mAlb <20 mg/L,n =33例)、Ⅱ组(mAlb 20~200 mg/L,n=35例)和Ⅲ组( mAlb>200 mg/L,n=39例),同期选取门诊体检的40例健康体检者作为对照组,测定其uLn-2、血肌酐、血尿素氮(BUN)、血清胱抑素C(Cys-C)水平。结果 uLn-2水平在对照组、Ⅰ组、Ⅱ组、Ⅲ组逐渐增高,四组间比较差异有统计学意义[(7.15±0.72)μg/L vs (9.72±0.81)μg/L vs(12.24±0.93)μg/L vs (15.05±1.03)μg/L,P<0.05];Ⅲ组血肌酐[(80.32±13.14)μmol/L]、BUN[(12.20±4.12) mmol/L]、Cys-C[(1.55±0.54) mg/L]明显高于Ⅱ组[(70.20±13.11)μmol/L、(7.10±3.04) mmol/L、(1.02±0.30) mg/L]、Ⅰ组[(65.47±12.50)μmol/L、(6.48±2.42)mmol/L、(0.90±0.22) mg/L]和对照组[(66.60±11.19)μmol/L、(6.31±2.71)mmol/L、(0.87±0.20) mg/L],差异均有统计学意义(P<0.05),但在对照组、Ⅰ组、Ⅱ组之间比较差异无统计学意义(P<0.05);LN患者的 uLn-2与 mAlb 之间呈正相关性(r =0.854,P <0.05)。结论uLn-2水平是检测LN患者早期肾功能损伤的敏感、有效的指标,且随着肾脏损伤程度的加重持续增高。
目的:探討尿脂質運載蛋白2(uLn-2)在狼瘡性腎炎(LN)患者早期診斷中的臨床意義。方法選取2010年3月至2013年9月內矇古自治區人民醫院腎內科收治的107例LN患者為研究對象,根據尿液中微量白蛋白(mAlb)水平分為Ⅰ組(mAlb <20 mg/L,n =33例)、Ⅱ組(mAlb 20~200 mg/L,n=35例)和Ⅲ組( mAlb>200 mg/L,n=39例),同期選取門診體檢的40例健康體檢者作為對照組,測定其uLn-2、血肌酐、血尿素氮(BUN)、血清胱抑素C(Cys-C)水平。結果 uLn-2水平在對照組、Ⅰ組、Ⅱ組、Ⅲ組逐漸增高,四組間比較差異有統計學意義[(7.15±0.72)μg/L vs (9.72±0.81)μg/L vs(12.24±0.93)μg/L vs (15.05±1.03)μg/L,P<0.05];Ⅲ組血肌酐[(80.32±13.14)μmol/L]、BUN[(12.20±4.12) mmol/L]、Cys-C[(1.55±0.54) mg/L]明顯高于Ⅱ組[(70.20±13.11)μmol/L、(7.10±3.04) mmol/L、(1.02±0.30) mg/L]、Ⅰ組[(65.47±12.50)μmol/L、(6.48±2.42)mmol/L、(0.90±0.22) mg/L]和對照組[(66.60±11.19)μmol/L、(6.31±2.71)mmol/L、(0.87±0.20) mg/L],差異均有統計學意義(P<0.05),但在對照組、Ⅰ組、Ⅱ組之間比較差異無統計學意義(P<0.05);LN患者的 uLn-2與 mAlb 之間呈正相關性(r =0.854,P <0.05)。結論uLn-2水平是檢測LN患者早期腎功能損傷的敏感、有效的指標,且隨著腎髒損傷程度的加重持續增高。
목적:탐토뇨지질운재단백2(uLn-2)재랑창성신염(LN)환자조기진단중적림상의의。방법선취2010년3월지2013년9월내몽고자치구인민의원신내과수치적107례LN환자위연구대상,근거뇨액중미량백단백(mAlb)수평분위Ⅰ조(mAlb <20 mg/L,n =33례)、Ⅱ조(mAlb 20~200 mg/L,n=35례)화Ⅲ조( mAlb>200 mg/L,n=39례),동기선취문진체검적40례건강체검자작위대조조,측정기uLn-2、혈기항、혈뇨소담(BUN)、혈청광억소C(Cys-C)수평。결과 uLn-2수평재대조조、Ⅰ조、Ⅱ조、Ⅲ조축점증고,사조간비교차이유통계학의의[(7.15±0.72)μg/L vs (9.72±0.81)μg/L vs(12.24±0.93)μg/L vs (15.05±1.03)μg/L,P<0.05];Ⅲ조혈기항[(80.32±13.14)μmol/L]、BUN[(12.20±4.12) mmol/L]、Cys-C[(1.55±0.54) mg/L]명현고우Ⅱ조[(70.20±13.11)μmol/L、(7.10±3.04) mmol/L、(1.02±0.30) mg/L]、Ⅰ조[(65.47±12.50)μmol/L、(6.48±2.42)mmol/L、(0.90±0.22) mg/L]화대조조[(66.60±11.19)μmol/L、(6.31±2.71)mmol/L、(0.87±0.20) mg/L],차이균유통계학의의(P<0.05),단재대조조、Ⅰ조、Ⅱ조지간비교차이무통계학의의(P<0.05);LN환자적 uLn-2여 mAlb 지간정정상관성(r =0.854,P <0.05)。결론uLn-2수평시검측LN환자조기신공능손상적민감、유효적지표,차수착신장손상정도적가중지속증고。
Objective To investigate the clinical significance of urinary lipid carrier protein-2 ( urinary lipocalin-2,uLn-2) in early diagnosis of patients with lupus nephritis (lupus nephritis,LN).Methods 107 patients with LN were divided into Ⅰ,Ⅱand Ⅲgroup according to the levels of urine albumin ,40 healthy subjects were selected as control group,the levels of uLn-2,serum creatinine,BUN,Cys-C were measured. Results The levels of uLn-2 in the control group,Ⅰgroup,Ⅱ group and Ⅲ group increased gradually were significant statistical differences among the four groups[(7.15 ±0.72)μg/L vs (9.72 ±0.81)μg/L vs (12.24 ±0.93)μg/L vs (15.05 ±1.03)μg/L,P <0.05]; The Cr[(80.32 ±13.14) μmol/L],BUN [(12.20 ±4.12) mmol/L],Cys-C[(1.55 ±0.54) mg/L] ofⅢ group were significantly higher than those in the control group[Cr,BUN,Cys-c were (66.60 ±11.19) μmol/L,(6.31 ±2.71)mmol/L,(0.87 ±0. 20) mg/L,respectively],Ⅰgroup [(65.47 ±12.50) μmol/L,(6.48 ±2.42) mmol/L,(0.90 ±0.22) mg/L],Ⅱgroup[(70.20 ±13.11)μmol/L,(7.10 ±3.04) mmol/L,(1.02 ±0.30) mg/L,P<0.05], but there were significant statistical differences among control group,Ⅰ,Ⅱgroup (P<0.05); The levels of uLn-2 in patients with LN were positively correlated with mAlb(r =0.854,P <0.05).Conclusion The level of uLn-2 can be considered as a sensitive and effective indicator to early monitor the renal dysfunction of cases with LN,and it continuously increases along with the worsening of worsening in renal dysfunction.